Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NST-0025
- Development stage
- Unknown
- Lead developer
- ai3Bio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
NST-0025 is a monoclonal antibody drug developed by Novasenta. It functions as an immunomodulator, meaning it modulates the immune system's activity. The specific molecular target and disease indications have not been disclosed publicly as of April 2025. The drug is in early-stage development and has not yet reached clinical approval or advanced clinical trial phases[1].
Beyond the preview
Go deeper on NST-0025.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NST-0025.